11月20日港股通创新药ETF工银（159217）份额增加8500.00万份

Group 1 - The core viewpoint of the article highlights the performance of the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217), which saw a slight increase of 0.21% in its value on November 20, with a trading volume of 722 million yuan [1] - The fund's total shares increased by 85 million to reach 3.865 billion shares, with a notable increase of 445 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 5.543 billion yuan, indicating a significant asset base for investors [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return rate of the National Index for Hong Kong Stock Connect Innovative Drugs [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with managers Liu Weilin and Jiao Wendong overseeing its operations [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 43.42%, although it has experienced a slight decline of 1.23% over the past month [1]